EMA
- Application: EMEA/H/C/004938
- Marketing authorisation holder: Mitsubishi Tanabe Pharma GmbH
- Local brand name: Radicava
- Indication: Treatment of amyotrophic lateral sclerosis.
- Pathway: orphan
- Status: withdrawn
🇪🇺 Radicava in European Union
Radicava (Radicava) regulatory status in European Union.
Marketing authorisation
Radicava in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Cardiovascular approved in European Union
Frequently asked questions
Is Radicava approved in European Union?
Yes. EMA has authorised it.
Who is the marketing authorisation holder for Radicava in European Union?
Mitsubishi Tanabe Pharma GmbH holds the EU marketing authorisation.